Lastly, when analyzing AML patients with and without MLL in comparison to the control group, the discriminative compounds were PC (28:0) and SMs ((d33:1) and (d18:1/12:0)) (Fig. 3C). The gene discussed is KMT2A; the disease is acute myeloid leukemia.